Education and Innovation in Cardiovascular Medicine
Webcast • Barcelona 2014

HDL mimetics: New promise in ACS?

Prof. Kausik Ray, London updates on novel research in the field of HDL-mimetics targeting the unstable plague in post ACS patients Watch
Webcast • Barcelona

IMPROVE-IT: Scenarios for understanding the results

Prof. Chris Packard (Glasgow) reviews the potential implications of new LDL-c lowering clinical trial outcomes for ezetimibe and new therapeutic options such as PCSK9 inhibitors Watch
News • 9-9-2014 • ESC 2014 - Barcelona

NOAC safe alternative for vitamin K antagonist around cardioversion for AF

ESC 2014 In the X-VERT trial a similarly low incidence of CV events was seen with rivaroxaban to VKA and rivaroxaban shortened the delay of cardioversion. Read more
News • 9-9-2014

No long-term increased risk of bladder cancer with pioglitazone in type 2 diabetes

A 10-year post-marketing study in patients with type 2 diabetes demonstrated no statistically significant increased risk of bladder cancer to patients exposed to pioglitazone. Read more
Webcast • Barcelona

Innovating hypertension: targeting the underlying disease process

Prof. Bryan Williams (London) urges the need for innovation to control systolic BP in our aging population Watch
E-Learning •

When to use GPIIb/IIIa receptor antagonists: pre-, peri- or post MI intervention

Dr. Kurt Huber, Vienna with a lecture held during an EBAC accredited symposium dedicated to '20 years clinical use of GPIIb/IIIa receptor antagonists' at ESC 2014 in Barcelona Read more
News • 31-8-2014 • ESC 2014 - BARCELONA

Lower LDL levels in difficult-to-treat hypercholesterolemic patients with new agent

Treatment with a new PCSK9-antibody in addition to standard therapy gets majority of high-risk patients (including HeFH) at LDL target (ODYSSEY program). Read more
News • 9-9-2014 • ESC 2014 - Barcelona

High intensity statin reduces atheroma volume in patients with acute STEMI

ESC 2014 13 Months of high dose rosuvastatin halts progression of atherosclerosis in non-culprit vessels, but no change of plaque phenotype was observed. Read more

Statins appear renoprotective in subjects with CVD, with or without chronic kidney disease

9-9-2014 • Amarenco P et al., Stroke. 2014
eGFR improved within a year of atorvastatin treatment in subjects with known coronary heart disease, and during up to 6 years of follow-up. Diabetic patients also have renal benefit. Read more
E-Learning •

Selective use of platelet glycoprotein IIb/IIIa inhibition

Dr. Jean-Philippe Collet, Paris with a lecture held during an EBAC accredited symposium dedicated to '20 years clinical use of GPIIb/IIIa receptor antagonists' at ESC 2014 in Barcelona Read more
E-Learning •

20 years clinical use of GP IIb/IIIa receptor antagonists

Prof J Wouter Jukema, Leiden, provides an introduction to a symposium that outlines the key milestones of GPI development and provides an up-todate overview of the clinical applicability of these drugs. Read more
News • 31-8-2014 • ESC 2014 - Barcelona

New LDL-lowering agent is consistently effective and safe in hypercholesterolemia

ESC 2014 The PCSK9 antibody alirocumab shows a consistent and safe decrease in LDL-C in high risk patients, and may show fewer cardiovascular events compared to placebo, when added to standard therapy. Read more